The Cooper Companies, Inc.

Can you explain this business to a smart friend in 2 minutes?

The Cooper Companies (COO) operates in two primary segments: CooperVision and CooperSurgical. CooperVision, the larger segment, manufactures and markets a comprehensive range of contact lenses, from standard spherical lenses to specialized toric and multifocal lenses for conditions like astigmatism and presbyopia, serving a global market. CooperSurgical focuses on women's and family healthcare, providing medical devices for surgical and office use, fertility products and services (including consumables, equipment, and genetic testing), and contraception like PARAGARD. Essentially, COO is a diversified healthcare company with a strong presence in vision correction and a growing footprint in women's health. They generated $3.59B in revenue in FY23, with a gross margin of 65.6% and net income of $294.2M.

Does the customer like the product? What is the evidence?

Based solely on the provided financial data, it's difficult to definitively assess direct customer sentiment. However, the consistent revenue growth suggests ongoing demand for their products. Revenue grew 5.1% YoY to $3.59B in FY23, and is projected to reach $4.09B in FY25. This indicates that customers are continuing to purchase their contact lenses and women's health products. The high gross margin, consistently above 60% (65.6% in FY23), also implies a degree of pricing power and perceived value, which often correlates with customer satisfaction. Without deeper qualitative research into customer reviews, market share trends, or competitive product comparisons, we cannot provide more direct evidence of customer preference. However, the continued revenue scale and growth suggest their products meet market needs.

Will this business exist in 10 years? Will it be bigger or smaller?

Yes, The Cooper Companies will almost certainly exist in 10 years. Both contact lenses and women's healthcare are fundamental, recurring needs that are not susceptible to technological obsolescence in the near term. The company has a substantial market capitalization of $13.98B and a global operational footprint. However, whether it will be bigger or smaller is the critical question, and the current trend points to structural challenges. The deterministic judgment highlights a 'value trap' situation, citing 'structural decline' and 'quality deteriorating.' Specifically, ROIC is trending down (currently 4.0%), and gross margins have declined from 66.9% in 2021 to a projected 60.7% in 2025. While revenue is growing, EPS growth has been negative (-4.6% YoY in FY23, and projected EPS of $1.88 in FY25 is below the $1.96 in FY22). This suggests that while the market for their products persists, their competitive advantage and profitability are eroding. Without a clear catalyst to reverse these declining quality metrics, the business is likely to be smaller in terms of profitability and market value in 10 years, even if revenue continues to grow modestly.

What is the 1 thing that matters most about this investment?

The single most critical factor for The Cooper Companies is the deteriorating quality of its earnings, specifically the declining trend in Gross Margin and Return on Invested Capital (ROIC). The deterministic judgment explicitly states: 'Both ROIC and gross margin trending down without earnings depression — structural decline.' Gross margin has fallen from 66.9% in 2021 to a projected 60.7% in 2025. While the company is generating revenue growth (5.1% YoY in FY23), this is not translating into sustainable, growing profitability. EPS has declined from $59.73 in 2021 (due to a one-time gain) to $1.49 in 2023, with a projected $1.88 in 2025, which is still below the $1.96 seen in 2022. This erosion of profitability and capital efficiency indicates a weakening competitive position. Without a reversal of these trends, the business's intrinsic value will continue to decline, regardless of top-line growth.

Is there a clear reason the stock is cheap, and is that reason temporary or permanent?

The stock is not cheap. While the P/E ratio is listed as 0.00x due to the one-time gain in 2021 distorting trailing earnings, the EV/EBITDA of 15.81x is not indicative of a 'cheap' stock, especially for a business with deteriorating quality. The deterministic judgment explicitly states: 'Buying because it looks cheap on P/E. The earnings are declining and the competitive advantage is eroding. A low P/E on deteriorating earnings is not cheap — it is a trap.' The market may be correctly pricing in the fundamental deterioration. The reason for the perceived 'cheapness' (if one were to look at trailing EPS post-2021) is the declining earnings power and eroding competitive advantage, evidenced by falling gross margins (from 66.9% in 2021 to projected 60.7% in 2025) and a declining ROIC (currently 4.0%). This is a structural issue, indicating a permanent, not temporary, impairment of quality unless a significant strategic shift or catalyst emerges. The market is likely recognizing this erosion of quality, making the current valuation a reflection of these underlying business challenges rather than a temporary mispricing.

What is the situation type?

The situation type for Cooper Companies (COO) is a 'value trap.' This classification is driven by the apparent cheapness on some trailing metrics, which masks a fundamental deterioration in business quality. The market is currently pricing COO at an EV/Revenue of 4.07x and EV/EBITDA of 15.81x on FY25 projected revenue of $4.09B and EBITDA derived from a 16.7% operating margin. While these multiples might appear reasonable in isolation, they become problematic when considering the declining profitability and competitive standing. The core issue is that a low P/E on deteriorating earnings is not cheap; it is a trap, as the underlying earnings power is eroding.

What specific event or condition created this opportunity?

There is no identifiable 'opportunity' in the traditional sense for Marlowe Partners with COO, as the deterministic judgment clearly indicates a 'pass.' The conditions that *create the illusion* of an opportunity for less discerning investors are the seemingly low trailing valuation metrics (P/E, P/B, P/FCF are all 0.00x in the provided data, implying either negative or negligible earnings/book value/FCF relative to price, which is a red flag in itself). However, the actual condition creating this 'value trap' scenario is the structural decline in the company's competitive position and profitability. Specifically, both Gross Margin and Operating Margin have trended downwards from FY21 (66.9% GM, 17.3% OM) to FY25 projections (60.7% GM, 16.7% OM, though FY24 saw a temporary bump). More critically, the ROIC is cited as 'deteriorating' at 4.0%. This erosion of quality, rather than a specific event, is the underlying condition that makes COO a value trap, as the market may be correctly pricing in this decline.

What is the catalyst for the situation to resolve?

Given the classification as a 'value trap' and the 'pass' verdict, there is no clear, identifiable catalyst for a positive resolution that would make COO an attractive investment for Marlowe Partners. A resolution would require a fundamental reversal of the deteriorating quality trends, specifically a sustained improvement in ROIC and gross margins, indicating a re-establishment of competitive advantage. This would likely stem from a significant strategic shift, a successful new product cycle, or a decisive capital allocation move that meaningfully enhances the company's earnings power. Without such a catalyst, the situation is unlikely to 'resolve' in a way that generates superior returns; rather, the current trends suggest continued underperformance. The market is likely pricing in a continuation of these trends, and any positive resolution would require a disruptive change not currently visible in the provided data.

What is the timeline for resolution?

As there is no clear catalyst for a positive resolution, there is no discernible timeline. The deterioration of quality, evidenced by declining gross margins and ROIC, suggests a structural issue rather than a temporary cyclical downturn. Reversing such a trend typically requires years of consistent execution and strategic repositioning. For instance, a major turnaround could take 3-5 years, similar to how companies like IBM struggled for a decade to pivot from hardware to services. However, without a concrete plan or visible signs of stabilization, assigning a timeline is speculative. The current trajectory indicates a prolonged period where the business struggles to generate adequate returns on capital, making it unsuitable for investment until tangible evidence of a turnaround emerges.

What could prevent the catalyst from occurring?

The primary factor preventing a positive catalyst from occurring is the ongoing erosion of competitive advantage and internal operational inefficiencies, as signaled by the 'deteriorating' quality and declining gross margins. If Cooper Companies cannot innovate effectively in its contact lens and women's health segments, or if competitive pressures intensify beyond current levels, the declining trends will persist. Furthermore, poor capital allocation decisions by management, such as value-destructive acquisitions or inefficient R&D spending, could exacerbate the problem. The existing debt load of $2.54B, while manageable with a 1.89x current ratio and 6.83x interest coverage, could become a constraint if profitability continues to decline, potentially limiting strategic flexibility. Ultimately, the absence of a clear strategic pivot or a significant market opportunity being exploited by management is the most significant impediment to any positive catalyst emerging.

Is there anything interesting about the capital structure?

The Cooper Companies' capital structure shows a significant increase in total debt over the past few years. Total Debt stood at $1.48B in 2021, jumped to $2.74B in 2022, and has since slightly decreased to $2.54B by 2025 (projected). This 71.6% increase in debt from 2021 to 2025 is notable, especially considering the corresponding decline in ROIC from 4.0% (implied for 2025, based on the deterministic judgment) and gross margin trends. The current D/E ratio is 0.34x, which on its own might appear manageable, but the context of declining earnings quality and increasing leverage raises concerns. The Enterprise Value ($16.66B) is significantly higher than the Market Cap ($13.98B), primarily due to this $2.43B in Net Debt, indicating that debt holders represent a material claim on the company's assets and earnings.

What is the debt maturity schedule? Any near-term refinancing risk?

The provided data does not include a detailed debt maturity schedule. Therefore, it is impossible to assess near-term refinancing risk with the current information. To determine this, we would need to review the company's latest 10-K filing, specifically the long-term debt footnotes, to identify upcoming principal payments and their associated interest rates. Without this, any judgment on refinancing risk would be speculative and unreliable.

Can the company service its debt in a downturn (stress test)?

The company's Interest Coverage Ratio is 6.83x, which appears healthy on its face. However, this is based on current operating income and assumes stable profitability. In a downturn, with deteriorating quality and declining margins (Gross Margin declined from 66.9% in 2021 to 60.7% in 2025, and Operating Margin from 17.3% to 16.7% over the same period), operating income would likely compress further. For example, if operating income were to halve, the interest coverage would drop to approximately 3.4x. While still above 1x, this would significantly reduce the margin of safety, especially given the increased debt load. The company's Free Cash Flow (FCF) has also been volatile, dropping from $524.2M in 2021 to $215.0M in 2023, before recovering to a projected $433.7M in 2025. This volatility, coupled with the increasing debt, suggests that a severe downturn could strain debt servicing capacity, particularly if FCF generation falls below the cost of debt, which is not explicitly stated but can be inferred from interest expense. A detailed stress test would require understanding the fixed vs. variable nature of costs and the sensitivity of revenue to economic cycles, which is not fully available here.

Is there capital structure optionality (activist potential, excess cash)?

Based on the provided data, there is limited capital structure optionality. The company holds only $110.6M in cash against $2.54B in total debt, resulting in a Net Debt of $2.43B. This cash balance is not 'excess' in the context of its debt load; it's a necessary operational buffer. There is no indication of significant hidden assets or underappreciated segments in the balance sheet data that would suggest activist potential from a capital structure perspective. The focus would likely be on operational improvements rather than financial engineering. The 'value_trap' signal and 'deteriorating quality' further reduce the likelihood of attracting constructive activist interest focused on unlocking capital structure value.

What is the net debt / EBITDA ratio and how does it compare to peers?

The provided data includes EV/EBITDA of 15.81x and Net Debt of $2.43B. While EBITDA is not explicitly given, we can estimate it. Given EV = Market Cap + Net Debt, and EV/EBITDA = 15.81x, we can derive EBITDA as EV / 15.81 = $16.66B / 15.81 = ~$1.05B. Therefore, the Net Debt / EBITDA ratio is approximately $2.43B / $1.05B = ~2.31x. This ratio is generally considered moderate for a healthcare company. However, without peer comparison data, it's difficult to definitively assess if this is high or low relative to its industry. More critically, the 'deteriorating quality' and declining ROIC suggest that even a moderate leverage ratio could become problematic if the earnings power continues to erode. A comparison with direct competitors in contact lenses (e.g., Alcon, Johnson & Johnson Vision) and women's health (e.g., Hologic, CooperSurgical's specific competitors) would be essential to contextualize this leverage.

How does the business make money? What is the revenue formula (Units × Price)?

The Cooper Companies generates revenue through the sale of contact lenses (CooperVision segment) and medical devices, fertility products, and related services for women's healthcare (CooperSurgical segment). The revenue formula is fundamentally (Units Sold × Average Selling Price) across these two distinct segments. For CooperVision, this means the volume of spherical, toric, and multifocal contact lenses sold multiplied by their respective prices. For CooperSurgical, it's the volume of medical devices (e.g., PARAGARD, uterine manipulators), fertility consumables, and genomics services provided, each multiplied by their prices. The company's global footprint across the Americas, Europe, Middle East, Africa, and Asia Pacific indicates a diversified geographic revenue base. The provided data does not break down revenue by units or average selling price, nor does it segment revenue by product line or geography, making a precise 'Units × Price' calculation impossible with the given information. Additional research would require segment-level revenue breakdowns and product volume data to fully disaggregate this formula.

What are the unit economics (CAC, LTV, payback period if applicable)?

The provided data is insufficient to calculate specific unit economics such as Customer Acquisition Cost (CAC), Lifetime Value (LTV), or payback period. These metrics are typically derived from detailed sales and marketing expenses, customer churn rates, and average revenue per customer, none of which are available in the provided financial summary. Cooper's business model, involving both B2B sales to healthcare professionals (e.g., optometrists, gynecologists) and potentially some B2C aspects for contact lenses, suggests that CAC might be related to sales force effectiveness, marketing to professionals, and brand awareness campaigns. LTV would depend on customer loyalty (e.g., repeat contact lens purchases, continued use of CooperSurgical products). Without granular data on customer acquisition channels, customer retention, and per-customer revenue, any calculation of these unit economics would be speculative. This is a critical gap for understanding the underlying profitability of acquiring and retaining customers in each segment.

What is the fixed vs variable cost structure (operating leverage)?

The Cooper Companies exhibits a cost structure with significant operating leverage, typical for a medical device and contact lens manufacturer. Gross margins are consistently high, ranging from 60.7% to 66.9% over the last five years, indicating that a substantial portion of costs are variable (Cost of Goods Sold). However, the spread between Gross Margin and Operating Margin (which includes fixed costs like R&D, SG&A) is considerable, ranging from 44.0% to 51.6%. For example, in FY2025, Gross Margin is 60.7% while Operating Margin is 16.7%, suggesting that approximately 44% of revenue is consumed by fixed operating expenses. This implies that once fixed costs are covered, incremental revenue should lead to a disproportionately higher increase in operating income. The company's ability to maintain high gross margins despite fluctuating operating margins suggests that while COGS are largely variable, the substantial fixed costs in R&D, manufacturing overhead, and global sales infrastructure are a significant component of their cost base. The decline in operating margin from 17.3% in FY2021 to 16.7% in FY2025 (despite a higher gross margin in FY2025 compared to FY2022) suggests that fixed costs are growing at a rate that is either outpacing revenue growth or becoming less efficient, eroding the benefit of the high gross margin.

What are margin trends over the last 5 years and why?

Cooper Companies has experienced a mixed and generally deteriorating trend in its profitability margins over the last five years. Gross Margin peaked at 66.9% in FY2021, then declined to 64.7% in FY2022, recovered slightly to 65.6% in FY2023, and is projected to be 66.6% in FY2024 before dropping to 60.7% in FY2025. This projected sharp decline in GM for FY2025 is concerning and suggests increasing cost pressures or pricing challenges. Operating Margin has shown a clearer downward trend, decreasing from 17.3% in FY2021 to 15.3% in FY2022, 14.8% in FY2023, recovering to 18.1% in FY2024, but then projected to fall to 16.7% in FY2025. Net Margin has also suffered, plummeting from 59.73% in FY2021 (likely an anomaly due to a one-time gain or tax benefit, given the EPS of $59.73) to a more normalized 9.2% in FY2025. Excluding the FY2021 anomaly, Net Margin was 11.6% in FY2022, 8.2% in FY2023, and 10.1% in FY2024, showing significant volatility and a general erosion. The primary 'why' for these trends, particularly the operating margin decline, appears to be a combination of increasing operating expenses (SG&A, R&D) relative to revenue growth, and potential competitive pressures impacting pricing or cost of goods. The 'DETERMINISTIC JUDGMENT' directly states that both ROIC and gross margin are 'trending down without earnings depression — structural decline,' indicating that the market is observing these margin compressions as a sign of eroding competitive advantage and not merely cyclicality.

What is the FCF conversion rate (FCF / Net Income)?

The Free Cash Flow (FCF) conversion rate (FCF / Net Income) for Cooper Companies has been highly volatile and inconsistent over the last five years, indicating a lack of predictable cash generation from reported earnings. Calculating this metric: * FY2021: $524.2M / $2.94B = 17.8% (Note: Net Income was exceptionally high this year, skewing the ratio) * FY2022: $450.4M / $385.8M = 116.7% * FY2023: $215.0M / $294.2M = 73.1% * FY2024: $288.1M / $392.3M = 73.4% * FY2025: $433.7M / $374.9M = 115.7% Excluding the anomalous FY2021 Net Income, the FCF conversion has ranged from 73.1% to 116.7%. While a conversion rate above 100% is generally positive, indicating strong cash generation, the significant fluctuations year-over-year (e.g., 116.7% to 73.1% and back to 115.7%) suggest that earnings quality is inconsistent or that capital expenditure requirements and working capital changes are highly variable. The overall trend, particularly the dip in FY2023, aligns with the 'deteriorating quality' assessment, as inconsistent FCF generation makes it difficult to project future capital allocation capabilities or debt repayment capacity. The average FCF conversion over the last four normalized years (FY22-25) is approximately 94.7%, which is acceptable, but the volatility is a red flag for predictability.

What percentage of revenue is recurring vs one-time?

The provided data does not explicitly break down revenue into recurring versus one-time components. However, based on the business description, CooperVision's contact lens sales inherently possess a high degree of recurring revenue due to the consumable nature of the product and the need for regular replacement. CooperSurgical's medical devices and fertility products likely have a mix; consumables and services (like genetic testing) would be recurring, while equipment sales would be more one-time. Without specific segment-level revenue breakdowns or product-specific sales data, it is impossible to quantify the exact percentage. Further research would require examining the company's 10-K filings for segment details on product types and sales models, particularly for CooperSurgical's offerings.

What are customer retention/renewal rates?

The provided data does not include specific customer retention or renewal rates for either the CooperVision or CooperSurgical segments. This information is critical for assessing revenue predictability, especially for the contact lens business where brand loyalty and prescription renewals drive repeat purchases. To obtain this, one would typically need access to detailed operational metrics from the company's investor presentations or annual reports, which are not present in this dataset. Without these figures, we cannot definitively quantify customer stickiness or churn.

What happened to revenue during 2008-2009 and 2020?

The provided historical financials only cover the period from 2021 to 2025. Therefore, the data does not allow for an analysis of revenue performance during the 2008-2009 global financial crisis or the 2020 COVID-19 pandemic. To understand the company's resilience during these significant economic and public health disruptions, one would need to consult historical financial statements from those specific years. This is a crucial gap in assessing the cyclicality and stability of COO's revenue streams.

What is the contract length and renewal pattern?

The provided information does not detail contract lengths or renewal patterns for Cooper's products or services. For CooperVision, contact lenses are typically purchased on a recurring basis (e.g., monthly, quarterly, or annually) based on prescription cycles, implying a high frequency of 'renewal' through repeat purchases rather than formal contracts. For CooperSurgical, medical devices and fertility services might involve longer-term agreements with healthcare providers or clinics, but the specifics are not disclosed. Understanding these patterns would require deeper investigation into the sales models for each product line, likely found in detailed business segment descriptions or discussions with management.

How concentrated is the customer base (top 10 customers as % of revenue)?

The provided data does not offer any information regarding customer concentration, such as the percentage of revenue derived from the top 10 customers. Given the nature of its businesses – contact lenses sold through eye care professionals and medical devices/fertility products sold to healthcare systems and clinics – it is plausible that Cooper has a diversified customer base rather than high concentration with a few large clients. However, without specific disclosure from the company's 10-K or investor presentations, this remains an assumption. High customer concentration would introduce significant revenue risk, while a diversified base would enhance stability.

Does it have a moat? What type (network effects, switching costs, scale, brand, regulatory)?

The Cooper Companies (COO) operates in segments that historically benefit from moderate competitive advantages, primarily driven by regulatory barriers, product differentiation, and moderate switching costs in specialized medical devices. In CooperVision, contact lenses are medical devices subject to FDA approval, creating a regulatory barrier to entry. Brands like Biofinity and MyDay have established recognition among optometrists and patients, suggesting a degree of brand loyalty. In CooperSurgical, specialized medical devices for women's health and fertility also face regulatory hurdles and require specialized training, implying some switching costs for healthcare professionals. However, the deterministic judgment indicates 'deteriorating quality' and 'value_trap' signals, specifically 'Both ROIC and gross margin trending down without earnings depression — structural decline.' This suggests that any historical moats are either weakening or insufficient to protect profitability against competitive pressures, as evidenced by the declining ROIC and gross margins over the last five years (GM from 66.9% in 2021 to 60.7% in 2025, OM from 17.3% to 16.7% over the same period, with a dip to 14.8% in 2023).

What is the ROIC and how does it compare to WACC? Is it above cost of capital?

The provided data explicitly states ROIC is 0.0% for the current period, with a trend of 'declining.' While the specific WACC is not provided, an ROIC of 0.0% is definitively below any reasonable cost of capital. Furthermore, the deterministic judgment highlights 'ROIC 4.0%, trend: declining' as a key indicator of deteriorating quality. This 4.0% ROIC, even if it represents a more accurate recent figure, is likely below the company's WACC, especially given its debt load of $2.54B and interest coverage of 6.83x, implying a non-trivial cost of debt. A sustained ROIC below WACC indicates that the company is destroying shareholder value with its incremental capital, a critical red flag for long-term investment and a direct contradiction to the requirement for a sustainable competitive advantage.

Does the company have pricing power? Evidence?

The evidence suggests Cooper Companies' pricing power is eroding. While medical device and contact lens companies typically possess some pricing power due to product differentiation and regulatory barriers, COO's declining gross margins (from 66.9% in 2021 to 60.7% in 2025) and operating margins (from 17.3% in 2021 to 16.7% in 2025, with a low of 14.8% in 2023) indicate an inability to fully pass through cost increases or maintain premium pricing in the face of competition. This trend, explicitly noted in the deterministic judgment as 'gross margin trending down without earnings depression — structural decline,' directly contradicts the presence of robust pricing power. If strong pricing power existed, these margins would likely be stable or improving, especially with revenue growth (5.1% YoY).

What is the market share and how is it trending?

The provided data does not include specific market share figures for either the CooperVision or CooperSurgical segments. Therefore, it is impossible to definitively state the company's market share or its trend. To assess this, additional research would be needed, specifically looking into industry reports, competitor disclosures, and management commentary regarding market positioning in contact lenses, women's health, and fertility markets. However, the observed decline in profitability metrics, particularly gross and operating margins, despite revenue growth, suggests that even if market share is stable or growing, it is not translating into improved unit economics or competitive strength.

Is the customer deeply embedded (high switching costs)?

Customers in both segments exhibit moderate switching costs, but these appear insufficient to prevent margin erosion. In CooperVision, contact lens wearers are often loyal to specific brands or types of lenses due to comfort, fit, and prescription stability. Optometrists, who prescribe these lenses, also have established relationships with specific manufacturers. In CooperSurgical, healthcare professionals using specialized medical devices and fertility products face training costs and workflow integration challenges when switching providers. For instance, PARAGARD, a long-acting contraceptive, implies high switching costs once implanted. However, the 'deteriorating quality' assessment, driven by declining ROIC and gross margins, indicates that these switching costs are not strong enough to protect the company's economic returns from competitive pressures. Competitors are likely offering compelling alternatives that overcome these moderate switching costs, or the market itself is becoming more commoditized, forcing price concessions.

Is the industry growing, stable, or shrinking?

Based on Cooper Companies' revenue growth, the underlying industries (contact lenses and women's health/fertility) appear to be growing, albeit modestly. COO's revenue grew 5.1% YoY in FY25, following 8.4% in FY24, 7.9% in FY23, and 13.3% in FY22. This suggests a stable to moderately growing market. However, the critical insight is that while the market is growing, COO's profitability metrics (Gross Margin and Operating Margin) have shown a declining trend over the past five years (GM from 66.9% in 2021 to 60.7% in 2025; OM from 17.3% in 2021 to 16.7% in 2025, with a low of 14.8% in 2023). This indicates that even in a growing market, Cooper is struggling to maintain or improve its competitive position, leading to a deterioration in the quality of its earnings.

What is the competitive structure (monopoly, oligopoly, fragmented)?

The provided data does not explicitly detail the competitive structure of either the contact lens or women's health/fertility markets. However, the declining gross and operating margins for Cooper Companies, despite revenue growth, strongly suggest that the contact lens market is likely an oligopoly with intense competition, or at least one where Cooper is losing share or pricing power. Major players like Johnson & Johnson (Acuvue), Alcon (Dailies, Air Optix), and Bausch + Lomb are formidable competitors. Similarly, the women's health and fertility segment (CooperSurgical) likely faces competition from specialized medical device companies and pharmaceutical firms. The observed margin compression implies that Cooper lacks significant monopolistic or strong oligopolistic pricing power, which would typically protect margins even with modest growth.

Is there consolidation potential? Who are likely acquirers?

The data does not provide direct evidence for consolidation potential or likely acquirers. However, in mature, moderately growing industries with margin pressure, consolidation is a common theme as companies seek scale efficiencies and reduced competition. Given Cooper's two distinct segments – CooperVision (contact lenses) and CooperSurgical (women's health) – there could be different consolidation dynamics. For CooperVision, larger players like Johnson & Johnson or Alcon might consider strategic acquisitions to gain market share or specific technology, though anti-trust concerns could arise. For CooperSurgical, larger diversified medical device companies or private equity firms might be interested in specific product lines. The declining ROIC (4.0% with a declining trend) suggests that Cooper's current structure may not be optimally generating returns, which could make it a target for an activist investor pushing for a breakup or sale of underperforming assets, or a strategic buyer looking to unlock value through integration. Without more granular segment data, identifying specific acquirers remains speculative.

What are the barriers to entry?

For the contact lens industry (CooperVision), barriers to entry are high due to significant R&D investment for new materials and designs, regulatory hurdles (FDA approvals), established distribution channels, and strong brand loyalty. Manufacturing requires specialized technology and scale. For the women's health/fertility segment (CooperSurgical), barriers are also substantial, including regulatory approvals for medical devices and pharmaceuticals, clinical trial costs, intellectual property protection, and established relationships with healthcare providers. These barriers typically protect incumbents and allow for sustained profitability. However, Cooper's declining gross and operating margins suggest that while these barriers exist, they are not sufficient to fully insulate the company from competitive pressures or to prevent erosion of its economic moat. The 'value trap' signal indicates that these barriers are not translating into a durable competitive advantage for Cooper in its current state.

Are there secular tailwinds or headwinds?

The contact lens market generally benefits from secular tailwinds such as an aging global population (increasing presbyopia), rising rates of myopia, and increasing disposable income in emerging markets. However, potential headwinds include increasing competition from laser eye surgery (LASIK) and the rise of online retailers putting pressure on pricing. For the women's health and fertility segment, secular tailwinds include increasing awareness and access to reproductive health services, rising infertility rates, and advancements in assisted reproductive technologies. Headwinds could include healthcare policy changes, pricing pressure from insurers, and ethical considerations surrounding certain fertility treatments. The fact that Cooper's profitability metrics are declining despite these potential tailwinds suggests that company-specific issues, such as competitive execution or product differentiation, are overriding broader industry growth, aligning with the 'value_trap' assessment.

Are there underappreciated business segments?

Based on the provided high-level business description, Cooper Companies operates in two segments: CooperVision (contact lenses) and CooperSurgical (women's health/fertility). The data does not provide granular segment-level financials such as revenue, gross margin, or operating income for each. Therefore, it is impossible to definitively identify an 'underappreciated' segment from the available information. To assess this, we would need to analyze segment-specific growth rates, profitability, and capital intensity, and compare them against market multiples for pure-play companies in each respective sub-industry. Without this breakdown, we cannot determine if one segment is masking the true value of another or if either is being undervalued by the market.

Is there margin expansion opportunity beyond current guidance?

The provided data shows a concerning trend in profitability. Gross Margin has declined from 66.9% in 2021 to 60.7% in 2025 (projected), and Operating Margin has similarly fallen from 17.3% to 16.7% over the same period, despite a projected rebound to 18.1% in 2024. This consistent erosion of gross and operating margins, coupled with a declining ROIC (currently 4.0%), strongly suggests a structural issue, not merely cyclical pressure. While the 2024 projection shows a temporary uptick, the overall trend indicates a lack of sustainable margin expansion. Any potential for margin expansion beyond current guidance would need to stem from a clear, identifiable catalyst such as a significant product innovation, a major cost restructuring, or a shift in pricing power. None of these are evident in the provided data. The 'deteriorating quality' signal suggests that the company is losing its ability to command higher margins or control costs effectively, making significant, unguided margin expansion highly improbable without a fundamental shift in competitive dynamics.

Are there hidden assets (real estate, IP, tax assets)?

The provided financial data does not offer any specific details regarding hidden assets such as undervalued real estate, unmonetized intellectual property, or significant net operating loss (NOL) carryforwards. The balance sheet shows Total Debt of $2.54B and Cash of $110.6M, with a Net Debt of $2.43B. A current ratio of 1.89x indicates reasonable short-term liquidity, but no extraordinary cash hoard or asset base is apparent. To identify hidden assets, we would need to conduct a detailed review of the company's fixed asset schedule, intellectual property portfolio, and tax filings. Without this deeper dive, there is no indication of significant hidden assets that could provide a valuation floor or upside optionality beyond the stated financials. Given the 'value_trap' situation and 'deteriorating quality' assessment, it is unlikely that substantial hidden assets are being overlooked by the market, as such assets typically become apparent in distressed situations.

Is there strategic value (M&A target potential)?

While Cooper Companies operates in attractive healthcare segments (contact lenses and women's health/fertility), the 'deteriorating quality' and declining ROIC (4.0%) significantly diminish its appeal as a premium M&A target. A potential acquirer would need to justify the $16.66B Enterprise Value against the declining profitability and competitive erosion. While the CooperVision segment holds a significant market share in contact lenses, and CooperSurgical has a niche in fertility, the overall trend of declining gross margins and operating margins suggests a business facing increasing competitive pressures or internal inefficiencies. An acquisition would likely be driven by synergy potential or a belief that a new owner could reverse the negative trends in quality and profitability. However, without a clear catalyst for quality improvement, as highlighted in the deterministic judgment, the strategic value as an M&A target at a significant premium is questionable. Any M&A interest would likely be opportunistic, targeting specific assets or market share rather than the entire entity at a premium valuation.

What growth optionality exists that is NOT in the base case?

The provided data shows revenue growth slowing from 5.1% YoY to a projected 4.9% from 2024 to 2025, suggesting a mature business with limited organic acceleration. While healthcare markets can offer long-term tailwinds (e.g., aging populations for vision care, increasing access to fertility treatments), the company's declining ROIC and margins indicate that it is struggling to capitalize on these trends profitably. Any significant 'growth optionality' not in the base case would need to come from disruptive innovation, successful entry into new high-growth geographies, or a major acquisition that fundamentally alters its competitive position and profitability profile. The current data does not provide any specific indications of such initiatives. The 'deteriorating quality' assessment implies that the company is losing its competitive advantage, making it difficult to identify unpriced growth optionality. Without evidence of new product pipelines, market expansion strategies, or R&D breakthroughs that could reverse the declining profitability trends, assuming significant unpriced growth optionality would be speculative and inconsistent with the overall assessment of a 'value_trap'.

Using Liquidation value / asset value floor, what is the fair value range?

A precise liquidation value for The Cooper Companies (COO) cannot be determined solely from the provided balance sheet data without a detailed breakdown of asset types, their market values, and associated liquidation costs. However, we can establish a rudimentary asset value floor based on Net Tangible Assets. Total Assets are not provided, but we have Total Debt of $2.54B and Cash of $110.6M. The P/B ratio is 0.00x, indicating that Book Value per Share is either negative or not readily available in this summary. Given the nature of COO's business – medical devices and contact lenses – a significant portion of its assets are likely intangible (intellectual property, brand value, customer relationships) or specialized fixed assets (manufacturing equipment) that would fetch a substantial discount in a liquidation scenario. For a true asset value floor, we would need to: 1) Obtain a detailed balance sheet to identify tangible assets (e.g., inventory, property, plant, and equipment) and their carrying values. 2) Apply conservative liquidation discounts to these tangible assets (e.g., 50-70% for PP&E, 20-50% for inventory). 3) Subtract all liabilities, including potential liquidation expenses. Without this granular data, any calculated 'liquidation value' would be highly speculative and likely misleading. The current market capitalization of $13.98B is significantly higher than the reported Total Debt of $2.54B, suggesting the market values the ongoing business, not its breakup value. This is consistent with a 'value trap' assessment where the business has significant operational assets but declining quality.

How does the current valuation compare to 3-year and 5-year history?

The current market capitalization of $13.98B at a share price of $71.08 reflects a significant decline from its peak. Looking at the historical financials, Net Income peaked in 2021 at $2.94B (EPS $59.73), driven by a one-time gain, but has since declined to $374.9M (EPS $1.88) in 2025. This dramatic shift in reported earnings makes trailing P/E ratios in recent years incomparable. If we consider EV/EBITDA, the current 15.81x is a premium relative to its historical performance if earnings were stable or growing. However, the reported EPS has fallen from $1.96 in 2022 to $1.88 in 2025, despite revenue growth from $3.31B to $4.09B over the same period. This indicates a significant deterioration in profitability and operating leverage. The current EV/Revenue of 4.07x is also at the lower end of what one might expect for a healthcare company with 60%+ gross margins, but the declining operating margin (from 17.3% in 2021 to 16.7% in 2025) and ROIC trend (declining from 4.0%) suggests a fundamental erosion of quality. The market is pricing in this decline, as evidenced by the 52-week range of $61.78-$89.83, with the current price near the lower bound. Compared to 2021, when the company reported massive net income, the current valuation is dramatically lower on an earnings basis, reflecting the market's re-evaluation of its earnings power and quality.

Is there an obvious negative paradigm on the company or sector?

Yes, there is a clear negative paradigm emerging for The Cooper Companies, specifically regarding its 'quality' metrics. The deterministic judgment explicitly states that 'Quality is deteriorating (ROIC 4.0%, trend: declining)' and 'gross margin trend: declining.' While the sector (Medical - Instruments & Supplies) generally benefits from stable demand, COO's internal metrics suggest a company-specific issue. Gross Margin has declined from 66.9% in 2021 to 60.7% in 2025 (projected), and Operating Margin has fallen from 17.3% to 16.7% over the same period, despite revenue growth. This indicates increasing cost pressures, potentially due to competitive intensity in contact lenses or challenges within CooperSurgical. The declining ROIC (4.0%) further confirms that the company is generating less return on its invested capital, a critical red flag for long-term value creation. This is not a sector-wide issue but a specific deterioration within COO, signaling an erosion of its competitive advantage and pricing power. The market is increasingly recognizing this, leading to the 'value trap' designation where a seemingly low valuation masks underlying fundamental decay.

Is it trading at a significant discount to comparable peers?

Without specific peer data, a definitive comparison is difficult. However, based on the provided valuation metrics, COO's EV/EBITDA of 15.81x is not necessarily a 'significant discount' for a company with declining quality and eroding margins. For context, high-quality medical device companies with stable growth and strong competitive advantages often trade at EV/EBITDA multiples in the high teens or even twenties. For a company exhibiting declining gross margins (from 66.9% to 60.7%) and ROIC (4.0% and declining), a 15.81x EV/EBITDA multiple might actually be generous, not a discount. The market is likely already applying a discount for the observed deterioration in quality. If peers in the contact lens or women's health space are maintaining or improving their margins and ROIC, COO's current multiple, while lower than its historical peak, may still not represent a 'significant discount' relative to its *actual* intrinsic value given its trajectory. The 'value trap' signal suggests that what appears cheap on paper (e.g., a lower multiple than some peers) is simply a reflection of its diminishing quality, not a mispricing.

What would the market need to believe for the current price to be correct?

For the current price of $71.08 (Market Cap $13.98B) to be correct, the market would need to believe that the observed deterioration in quality—specifically the declining gross margins (from 66.9% in 2021 to 60.7% in 2025) and operating margins (from 17.3% to 16.7%), and the declining ROIC (4.0%)—is either temporary, has bottomed out, or is fully priced into the current valuation. The market would be accepting that future earnings growth will be modest (EPS projected to be $1.88 in 2025, down from $1.96 in 2022) and that the company's competitive position, while weakened, is not permanently impaired. Essentially, the market would be signaling that COO is a mature, slow-growth business with stable, albeit lower, profitability, and that its current earnings power (normalized around $0.4B) justifies an EV/EBITDA multiple of 15.81x. It implies that the current price accurately reflects the risk of further quality erosion against the potential for stabilization at these lower profitability levels. The market is not pricing in a strong rebound in profitability or a re-acceleration of high-quality growth, but rather a continuation of the 'deteriorating quality' trend at a slower pace.

Is this a small/mid cap with limited analyst coverage?

No, The Cooper Companies (COO) is not a small/mid-cap company with limited analyst coverage. Its Market Cap of $13.98 billion places it firmly in the large-cap category, well above the typical thresholds for mid-cap ($2B-$10B) or small-cap (under $2B). The provided data indicates '0 total holders' for institutional ownership, which is highly unusual and likely a data error. Given its NASDAQ listing, long IPO history (1983), and large market capitalization, it is improbable that institutional ownership is truly zero or that analyst coverage is limited. We would expect robust coverage from major investment banks and asset managers for a company of this size. Further research would be required to verify the institutional ownership data, as the 'N/A' and '0 total holders' is a clear anomaly.

Have investors been burned in this name before (creating anchoring bias)?

Yes, it is highly probable that investors have been burned in COO, contributing to an anchoring bias, particularly given the recent performance. The stock's 52-week range is $61.78-$89.83, and the current price of $71.08 is closer to the bottom of this range. More critically, the EPS has declined significantly from $59.73 in 2021 to $1.88 in 2025 (projected), and Net Income has fallen from $2.94 billion in 2021 to a projected $374.9 million in 2025. This dramatic collapse in reported earnings, even if partially due to non-recurring items in 2021, would have certainly punished shareholders who bought into the previous earnings power. The 'value_trap' situation and the 'Consensus Mistake' of contrarian investors buying based on seemingly cheap trailing multiples reinforce this, suggesting a history of disappointment for those who bought too early on perceived value.

Has the company been recently transformed (market may not have adjusted)?

The provided data does not indicate a recent, significant transformation that the market may be mispricing. The company operates in two segments, CooperVision (contact lenses) and CooperSurgical (women's healthcare), which appear to be long-standing core businesses. While there's a reference to 'Conversion of Exercise of derivative security' for insiders, this does not suggest a fundamental business transformation. The declining ROIC and gross margins, coupled with the 'value_trap' verdict, suggest a business facing structural headwinds rather than a positive transformation. If there were a recent, material strategic shift, acquisition, or divestiture, it is not evident in the provided financials or description. We would need to review recent investor presentations and annual reports for any such strategic pivots.

Are there forced sellers (index deletion, spin-off, sector panic)?

There is no direct evidence in the provided data to suggest the presence of forced sellers for COO. The company is a large-cap NASDAQ-listed entity, making an index deletion less likely unless its market cap dramatically shrinks or it fails to meet listing requirements. There is no mention of a spin-off or a specific sector panic impacting Medical Instruments & Supplies or Healthcare broadly that would trigger forced selling. While the 'value_trap' situation implies investor disillusionment, this typically results in voluntary selling rather than forced liquidation by institutional mandates. Without specific news or regulatory filings indicating these events, we cannot confirm forced selling pressure.

Is the hypothesis researchable (can we get an edge through primary research)?

Yes, the hypothesis that COO is a value trap due to deteriorating quality is highly researchable, and an edge can be gained through primary research. The core issue is the 'deteriorating quality' (ROIC 4.0%, declining trend; gross margin trend: declining). To validate this, we would need to understand the competitive dynamics in both the CooperVision and CooperSurgical segments. For CooperVision, this means assessing new product pipelines, pricing power against competitors like J&J Vision, Alcon, and Bausch + Lomb, and the impact of evolving consumer preferences (e.g., daily disposables, myopia management). For CooperSurgical, understanding the competitive landscape for PARAGARD, fertility products, and other medical devices is crucial. Primary research would involve speaking with ophthalmologists, optometrists, OB/GYNs, and fertility specialists to gauge product preference, brand loyalty, and the effectiveness of COO's sales channels. We would also need to analyze competitor financial reports to understand industry-wide trends versus company-specific issues. This qualitative understanding of competitive advantage and customer reality is essential to confirm or refute the 'permanent impairment of competitive position' risk.

Is management a material owner in the business? Are they buying or selling?

Based on the provided data, there is no indication of material insider ownership. The 'Insider Activity' section lists 'Buys: 0' and 'Sells: 0'. While there are records of 'Conversion of Exercise of derivative security' for executives like Brian G. Andrews, Colleen E. Jay, and Daniel G. McBride, and 'Purchase 0 shares' for Lawrence Erik Kurzius and Cynthia L. Lucchese, these entries explicitly state '0 shares' or are conversions of derivatives, not open market purchases of common stock. This suggests no recent or material personal capital commitment by management. The data is insufficient to assess historical material ownership, but current activity shows no conviction from management's personal capital.

Does management have a track record of good capital allocation?

The provided data suggests a concerning trend in capital allocation. Total Debt has increased significantly from $1.48B in 2021 to $2.54B in 2025 (projected), while Cash balances have remained relatively flat, hovering around $100-140M. This indicates a substantial increase in net debt. Concurrently, ROIC is trending down, from an unspecified higher base to 4.0% currently, signaling that the increased capital deployment is not generating adequate returns. This pattern of increasing debt without commensurate improvement in profitability or efficiency of capital use points to a poor track record of capital allocation. A good capital allocator would demonstrate improving returns on invested capital or a more disciplined approach to debt management.

Does management have a track record of hitting guidance?

The provided data does not contain specific guidance targets or historical comparisons of actual results against past guidance. Therefore, it is impossible to assess management's track record of hitting guidance. Additional research would be required to review past earnings calls and investor presentations to compare management's projections with subsequent actual financial outcomes.

Is management promotional or operational?

The provided financial data and insider activity do not offer direct insight into whether management is promotional or operational. There are no quotes, statements, or communication patterns available to make this determination. An assessment would require reviewing investor presentations, earnings call transcripts, and public statements to analyze the tone and focus of management's communication. However, the declining ROIC and gross margins, despite revenue growth, suggest operational challenges that may be masked by promotional language if present.

Has there been recent management change and what does it signal?

The provided data does not indicate any recent management changes. Albert G. White is listed as the current CEO, and there is no information about his tenure or any recent executive appointments or departures. Without this information, we cannot assess what any potential changes might signal. Further investigation into the company's executive history would be necessary.

What is the draconian case (everything goes wrong)?

The draconian case for Cooper Companies is a continued, structural decline in both segments, leading to a permanent loss of competitive advantage and an inability to service its debt obligations. Specifically, the 'deteriorating quality' signal (ROIC trending down, gross margin trending down from 66.9% in 2021 to 60.7% in 2025E) indicates that the company's core business is losing its pricing power and efficiency. In this scenario, the current EV/EBITDA of 15.81x would compress significantly, potentially to a distressed multiple of 5-7x EBITDA, reflecting a business in secular decline. Given FY25E EBITDA (implied from EV/EBITDA and EV) is ~$1.05B ($16.66B EV / 15.81x), a 5x EBITDA multiple would value the enterprise at ~$5.25B. Subtracting the Net Debt of $2.43B, this would leave equity value of ~$2.82B, or ~$14.45 per share ($2.82B / 195.1M shares). This represents an ~80% decline from the current price of $71.08. Furthermore, with Total Debt at $2.54B and Interest Coverage at 6.83x, a significant drop in EBITDA could lead to covenant breaches, forcing asset sales at distressed prices or even bankruptcy, especially if refinancing becomes difficult in a higher interest rate environment. The 'What would kill it' verdict explicitly states 'Permanent loss of competitive advantage' and 'Covenant breach or inability to refinance' as key risks, which are central to this draconian outcome.

What is the floor to value (asset value, liquidation value)?

Given the 'value_trap' situation and the 'Liquidation value / asset value floor' method specified, we must assess the tangible asset base. Cooper Companies has Total Assets of ~$10.5B (implied from D/E of 0.34x and Total Debt of $2.54B, meaning Equity is ~$7.47B, so Assets = Debt + Equity). However, a significant portion of these assets are likely intangible (e.g., patents, brand value in contact lenses and medical devices) which would fetch little in a distressed liquidation. The balance sheet shows $110.6M in Cash and Current Ratio of 1.89x, suggesting decent short-term liquidity, but this doesn't guarantee asset value. Without a detailed breakdown of tangible vs. intangible assets and their specific market values in a liquidation scenario, a precise liquidation value is difficult to determine. We would need to strip out goodwill and other intangibles, then apply significant haircuts to inventory, property, plant, and equipment. Based on the 'deteriorating quality' and the 'value trap' signal, the market is unlikely to assign significant value to these assets beyond their immediate utility. Therefore, the floor is likely significantly below the current equity value, potentially approaching the Net Debt of $2.43B, suggesting equity holders could face substantial impairment or even total loss in a true liquidation scenario. Further research into the composition of 'Total Assets' and the market for used medical device manufacturing equipment and contact lens inventory would be critical to establish a more precise floor.

What is the maximum downside from current price?

Based on the draconian case, the maximum downside from the current price of $71.08 per share is approximately 80%, reaching an estimated equity value of ~$14.45 per share. This assumes a compression of the EV/EBITDA multiple to 5x, reflecting a business in structural decline with eroding competitive advantages. This outcome is directly supported by the 'deteriorating quality' signal (ROIC trending down, gross margin trending down), which suggests that the company's earnings power is not sustainable at current valuations. The market is currently pricing in a more optimistic scenario, but the signals indicate that this optimism is misplaced. A complete loss of equity value is also a possibility if the company cannot service its $2.54B in debt and is forced into bankruptcy, especially given the 'Covenant breach or inability to refinance' risk highlighted in the 'What would kill it' section.

Given the risk/reward, what position size is appropriate (Rule 10)?

Given the 'value_trap' situation, the clear signals of 'deteriorating quality' (declining ROIC and gross margins), and the significant downside risk of ~80% (or even total loss of equity), the appropriate position size is zero. Rule 10 states that position size should be inversely proportional to the probability of permanent capital loss. Here, the probability of permanent capital loss is unacceptably high due to the structural issues. The 'CONVICTION: pass — position size: none' verdict is definitive. Marlowe Partners avoids businesses where the quality is deteriorating and the downside is substantial, even if the market appears to be mispricing it. As the 'MARLOWE INSIGHT' states, 'The most dangerous mistake is underpaying for a bad business. Quality matters more than price.'

What would make us sell or reduce the position?

Since no position would be initiated in Cooper Companies due to its classification as a 'value_trap' with 'deteriorating quality' and significant downside risk, the question of selling or reducing a position is moot. We would not buy this business in the first place. The 'WHAT MUST BE TRUE' condition, 'No permanent impairment of competitive position,' is explicitly contradicted by the 'deteriorating quality' signal. Marlowe Partners invests only in high-quality businesses with strong competitive advantages. If, hypothetically, we had a position (perhaps from a prior, more favorable assessment), any further evidence of declining ROIC, continued gross margin erosion, increased debt burden without corresponding asset growth, or a clear failure in capital allocation by management (e.g., value-destructive M&A or share buybacks at inflated prices) would trigger an immediate exit. The 'WHAT WOULD KILL IT' factors – 'Permanent loss of competitive advantage,' 'Covenant breach or inability to refinance,' and 'Management credibility collapse' – would all be definitive sell signals.